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Abstract
Introduction: The objective of this prospective study was to assess short- and long-term efficacy of exercise
training (ET) as add-on to medical therapy in patients with connective tissue disease-associated pulmonary arterial
hypertension (CTD-APAH).
Methods: Patients with invasively confirmed CTD-APAH received ET in-hospital for 3 weeks and continued at
home for 12 weeks. Efficacy parameters have been evaluated at baseline and after 15 weeks by blinded-observers.
Survival rate has been evaluated in a follow-up period of 2.9 ± 1.9 years.
Results: Twenty-one consecutive patients were included and assessed at baseline, and after 3 weeks, 14 after 15
weeks. Patients significantly improved the mean distance walked in 6 minutes compared to baseline by 67 ± 52
meters after 3 weeks (p < 0.001) and by 71 ± 35 meters after 15 weeks (p = 0.003), scores of quality of life (p <
0.05), heart rate at rest, peak oxygen consumption, oxygen saturation and maximal workload. Systolic pulmonary
artery pressure and diastolic systemic blood pressure improved significantly after 3 weeks of ET. The 1- and 2-year
overall-survival rates were 100%, the 3-year survival 73%. In one patient lung transplantation was performed 6
months after ET.
Conclusion: ET as add-on to medical therapy is highly effective in patients with CTD-APAH to improve work
capacity, quality of life and further prognostic relevant parameters and possibly improves the 1-, 2- and 3-year
survival rate. Further randomized controlled studies are needed to confirm these results.
Trial registration: ClinicalTrials.gov: NCT00491309.
Introduction
Pulmonary arterial hypertension (PAH) is characterized
by increased pulmonary arterial pressure and pulmonary
vascular resistance [1] and can be associated with con-
nective tissue disease (CTD) such as systemic sclerosis
(SSc) [2] systemic lupus erythematosus (SLE) [3,4] and
mixed connective tissue diseases (MCTD) [5]. Asso-
ciated PAH (APAH) accounts for approximately half of
all patients with PAH [6] and has identical histological
findings as idiopathic PAH (IPAH). However, patients
with CTD-APAH seem to have a more severely affected
clinical phenotype than patients with IPAH. In the
American Registry to Evaluate Early and long Term
PAH Disease Management (REVEAL Registry), patients
with CTD-APAH had a significantly lower 6-minute
walking distance (6MWD), higher B-type natriuretic
peptide levels, lower diffusing capacity of carbon mon-
oxide and a lower 1-year survival rate than patients with
IPAH [7]. Despite advances in PAH treatment, CTD-
APAH continues to be progressive, with a 1-year on-
treatment mortality of approximately 12.5 to 17.0%
compared to 5.0 to 10.0% in IPAH [7,8]. In comparison
to other forms of APAH, patients with SSc-APAH
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demonstrated the worst 1-, 2- and 3-year survival rates
of 78.0%, 58.0% and 47.0%, respectively [9]. Patients
with CTD-APAH showed a significantly reduced time to
hospitalization, had a higher mean age at diagnosis and
higher incidence of comorbidities such as renal insuffi-
ciency and Raynaud’s phenomenon [7,10]. Furthermore,
randomized controlled studies reveal reduced efficacy of
PAH-targeted medication in this subgroup. For example,
in the BREATHE-1 study, bosentan therapy improved
baseline 6MWD by 46 meters in 102 patients with
IPAH, but only by 3 meters in the 33 patients with SSc-
APAH [11]. In addition, therapy with ambrisentan
resulted in significant improvement in the 6MWD
among patients with IPAH but not with CTD-APAH
[12]. Thus, patients with CTD-APAH in particular, may
have a high need for additional therapeutic tools to
address their exercise capacity, quality of life (QoL) and
survival.
Exercise training (ET) has shown beneficial effects on
exercise capacity and QoL in patients with PAH [13-15],
SLE [16] and in SSc [17-19]. ET also improved peak
oxygen consumption and World Health Organization
functional class (WHO-FC) in patients with pulmonary
hypertension [13], and possibly clinical outcomes, with
1- and 2-year survival rates of 100 and 95%, respectively
[14]. Up to now there has been no study focusing on
the effect of exercise training in patients with CTD-
APAH. The aim of this study was to prospectively assess
the effects of ET on prognostic relevant factors such as
6MWD and QoL, and to analyze the survival rate in a
cohort of patients with CTD-APAH.
Materials and methods
Study population and design
This prospective study investigated patients with CTD-
APAH who received exercise and respiratory training as
an add-on to disease-targeted medication, between
October 2007 and July 2011. Further inclusion criteria
were that patients must be aged between 18 and 80
years and classified as WHO-FC II to IV. Patients had
to be under optimized medical therapy for PAH
(endothelin-antagonists, inhaled or parenteral prosta-
noids, phosphodiesterase-5-inhibitors, anticoagulants,
diuretics, and supplemental oxygen) and for the under-
lying rheumatologic disease (prednisone, methotrexate)
for at least 2 months before entering the study. The
diagnosis of CTD-APAH was established at the partici-
pating pulmonary hypertension (PH) centers according
to current guidelines [1,15]. The rheumatologic diagno-
sis of each patient had been confirmed by specialized
rheumatologic centers. Patients with severe interstitial
lung disease were excluded from the study. All patients
underwent a detailed clinical work up including right
heart catheterization, and all gave written informed con-
sent for this study, which was approved by the Ethics
Committee of the University of Heidelberg.
Outcome measures
Efficacy parameters of ET were prospectively assessed at
baseline, week 3, and week 15 as described previously
[13,14]. The 6MWD was carried out under standardized
conditions [20]. Cardiopulmonary exercise testing and
stress Doppler echocardiography were performed during
supine bicycle exercise as described previously [13]. Sys-
tolic pulmonary artery pressure (sPAP), systolic (RRsys)
and diastolic (RRdiast) systemic blood pressure, work-
load, heart rate, ventilation, oxygen uptake (VO2), oxy-
gen pulse (VO2/heart rate), oxygen saturation and
carbon dioxide output (VCO2) were evaluated continu-
ously. The anaerobic threshold (AT) was detected with
the V-slope method. Gas exchange, Borg dyspnea index
(with 6 representing no exertion and 20 maximal exer-
tion) [21] and changes in WHO-FC were analyzed after
3 and 15 weeks. Health-related QoL assessment was
measured by the Short Form Health Survey question-
naire (SF-36) [22]; the baseline scores were compared to
the results after 15 weeks. The 6MWD and analysis of
the SF-36 questionnaire were performed by investigators
who were blinded to the patients’ clinical data, so that
the investigators did not know the values at any time
point.
Exercise training program
We performed a program especially developed for
patients with PH, that comprised at least 1.5 h/day ET
as described previously [13,14]. The program was started
for the first 3 weeks in the Rehabilitation Clinic, Koenig-
stuhl, Heidelberg. It consisted of interval bicycle erg-
ometer training at low workloads, mental gait training,
dumbbell-training of single muscle groups using low
weights (500 to 1000 g) and respiratory therapy 5 days/
week. The training was continued at home with at least
30 minutes/day at 5 days/week for the following 12
weeks. Patients were asked to continue with ET at home
after the 15-weeks-visit. In addition to physical training
patients received psychological support and performed
mental training to improve their perception of individual
physical abilities and limits. Physicians specialized in
rehabilitation medicine and PH experts closely super-
vised the training program as described before [13,14].
Adverse events were recorded whenever they occurred.
Oxygen saturation and heart rate were monitored con-
tinuously throughout the training and used to adjust the
training intensity. When patients’ oxygen saturation fell
below 90% during exercise they received supplemental
oxygen (3 to 10 L/min) throughout the training. At
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discharge from hospital after 3 weeks, patients received
an individualized training manual and ordered a bicycle
ergometer for use at home. All patients were asked to
keep close contact with the physicians involved in the
training program, and with their general practitioners
and the specialized center.
Follow-up assessment
In 2011 all participating patients were interviewed by
telephone using a half-structured questionnaire. The
patients were asked about their current symptoms for
WHO-FC, if and how they pursued ET at home,
whether they had any adverse events from ET, any
further cardiac events that might have occurred since
the last observation and current medication. Patients
who did not attend the last 15-week follow-up visit were
the reason for missing the examination. If the patient
was deceased, date of death was recorded and their rela-
tives and/or treating physicians were asked for the cause
and circumstances of death.
Statistical methods
The analyses were performed by a statistician (CF). The
within-group comparisons of baseline and weeks 3 and
15 for 6MWD, workload, Borg dyspnea index, para-
meters of gas exchange, systolic pulmonary arterial pres-
sure (sPAP), systemic blood pressures, heart rate as well
as summation and sub-scores of the SF-36 were com-
pared by the Wilcoxon rank test. Comparison of WHO-
FC at different time points was performed by the McNe-
mar-Bowden test. All tests were two sided and P-values
< 0.05 were considered statistically significant. Bonfer-
roni adjustment for multiple comparisons was per-
formed for the primary endpoints, 6MWD and QoL
parameters; P-values < 0.005 were considered significant.
All analyses were carried out using IBM SPSS V19 (IBM
Corp. Armonk, NY, USA). We describe in detail, the
patients who did not attend the 15-week measurement.
To access the consequences for the main efficacy para-
meter, 6MWD, we performed multiple imputations of
6MWD at 15 weeks within SPSS using the predictive
mean matching model, with age, peak oxygen consump-
tion, oxygen consumption at the AT, oxygen saturation
at maximal workload, systolic blood pressure at maximal
workload at baseline, 6MWD at baseline and 3 weeks,
and pain subscale of the SF-36 at baseline as explana-
tory variables. Kaplan-Meier estimates were used for
survival analysis with the 95% two-sided confidence
interval (CI) calculated using Greenwood’s formula. All
treated patients were included in the survival analysis.
Patients who died or underwent organ transplantation




We included 22 consecutive patients (Table 1). One
patient had to be excluded because she could not per-
form the examinations after week 3 and week 15, due to
upper airway infection. Thus, the final study group con-
sisted of 21 patients: 9 patients (43%) with SSc-APAH, 7
(33%) with SLE-APAH, 2 (10%) with MCTD and 3
Table 1 Baseline characteristics
Patients, number 21
Gender male/female 1 / 20
Age, years 52 ± 18
Height, cm 165 ± 6
Weight, kg 68 ± 11





TLCO, % 55 ± 18
FEV1%VC, % 78 ± 7
pO2, mmHg 69 ± 12
Mean 6-minute-walking distance, meter
386 ± 121
Differential Diagnosis, number (%)
Systemic sclerosis 8 (43%)




Pulmonary artery pressure, mmHg 49 ± 13
Pulmonary vascular resistance, dyn×sec×cm-5 789 ± 498
Right atrium pressure, mmHg 7 ± 3
Pulmonary artery oxygen saturation, % 62 ± 10
PCWP, mmHg 10 ± 5
Cardiac index, L×min×m-2 2.6 ± 0.6
PAH-targeted medication, number (%)
Endothelin receptor antagonists 12 (57%)
Phosphodiesterase-5-Inhibitors 15 (71%)
Prostanoids inhaled 3 (14%)
Prostanoids intravenous 1 (5%)
Calcium channel blockers 2 (10%)
Soluble guanyl cyclase-stimulator 3 (14%)
Combination therapy, number (%)
Monotherapy 8 (38%)
Dual therapy 10 (48%)
Triple therapy 3 (14%)
Results are presented as mean ± standard deviation unless stated otherwise
WHO: World Health Organization; FEV1%VC: forced expiratory volume in one
second/vital capacity; TLCO: carbon monoxide transfer factor; pO2: partial
oxygen pressure; PCWP: pulmonary capillary wedge pressure; MCTD: mixed
connective tissue disease.
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(14%) with other CTDs such as Jo-1 syndrome and
Sjöegren’s syndrome. Demographic data, diagnosis, func-
tional class, hemodynamic values, lung function and
medical therapy in the full study population are sum-
marized in Table 1. At baseline 9 patients (43%) were in
WHO-FC II, 7 (33%) were classified as WHO-FC III
and 5 (24%) as WHO-FC IV. Combination therapies,
including two to three PAH-targeted agents, were used
in 62% of patients (Table 1).
Assessment of training effects
ET significantly improved the 6MWD from 386 ± 121
(mean ± standard deviation (SD)) meters by 64 ± 47
meters after 3 weeks (P < 0.001) and by 71 ± 35 meters
after 15 weeks (P < 0.003) (Figure 1). All patients except
one improved their 6MWD (Figure 1). In the patient
with no increase in 6MWD the test was limited by her
hip joint osteoarthritis. However, in this patient other
parameters of physical exercise capacity improved dur-
ing the ET.
Nine patients (43%) referred from PH-centers other
than Heidelberg did not attend the visit after 15 weeks,
mainly due to the long traveling distance. Results
remained significant after multiple imputation of miss-
ing values for the 6MWD at 15 weeks using the expla-
natory variables as described in Methods. The
improvement in 6MWD ranged from 71 to 79 meters in
the imputation replications. Patients who did not attend
the assessment after 15 weeks had a significantly higher
peak oxygen consumption at the AT (716 ± 139 vs. 543
± 161 ml/min; P = 0.038) and a higher improvement in
6MWD (79 ± 62 vs. 50 ± 24 meters; P = 0.156) after 3
weeks. They did not differ significantly in other para-
meters such as demographics or parameters of right
heart catheterization. After Bonferroni adjustment,
improvement in 6MWD remained statistically
significant.
ET also significantly improved QoL parameters indi-
cated by the SF-36 subscale scores for physical function-
ing (P = 0.025), general health perception (P = 0.049),
social functioning (P = 0.008), mental health (P = 0.033)
and vitality (P = 0.021) (Figure 2, Table 2).
Mean peak oxygen consumption, peak oxygen con-
sumption/kg body weight, oxygen consumption at the
anaerobic threshold, and oxygen saturation at maximal
workload during cardiopulmonary exercise testing
increased significantly from baseline to 3 weeks and to
15 weeks (Table 2). Heart rate at rest significantly
decreased after 3 and 15 weeks. After 15 weeks patients
achieved significantly higher workloads with an increase
of maximal heart rate during cardiopulmonary exercise
testing and maximal systolic blood pressure. The Borg
scale remained unchanged although significantly higher
workloads and higher heart rates during exercise were
attained (Table 2 Figure 3). After 3 weeks of ET, mean
diastolic blood pressure and sPAP at rest were signifi-
cantly reduced (Table 2). C-reactive protein reduced in
trend, but not significantly, after 3 and 15 weeks,
Figure 1 Individual changes in six-minute-walking distance (6MWD) after 3 and 15 weeks exercise training. Using the Wilcoxon rank
test, P < 0.001 was obtained for the comparisons with baseline at week 3 (n = 21) and P = 0.003 for comparison to week 15 (n = 11). The
dashed line indicates the mean change from baseline in 6MWD (67 ± 52 meters and 72 ± 35 meters).
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whereas N-terminal prohormone of brain natriuretic
peptide (NT-proBNP) plasma-levels remained
unchanged. Seven patients improved their WHO-FC
after 15 weeks; five of them were reclassified as WHO-
FC IV. Nevertheless, the change in WHO-FC after 3
weeks and after 15 weeks compared to baseline was not
significant (P = 0.058 and P = 0.096, respectively), possi-
bly due to the small sample size.
Adverse events
During the 3-week in-hospital training, three patients
had adverse events as follows: gastrointestinal infection
with diarrhea (n = 1) and respiratory infections (n = 2).
In all three patients the infection was treated success-
fully so that they were able to continue the training pro-
gram after one or two weeks. All other patients (81%)
tolerated the ET well. There were no signs of clinical
worsening or right heart failure during the in-hospital
program.
Follow-up and survival
Follow-up data were obtained after 2.9 ± 1.9 years (Fig-
ure 4). One patient had been listed for lung transplanta-
tion before starting the rehabilitation program. She
improved her walking distance by about 88 meters after
3 weeks, but did not perform the examination after 15
weeks due to the long traveling distance. However, she
required lung transplantation 6 months later. Between
2.8 and 5.0 years after in-hospital rehabilitation, two
patients died due to PAH and right heart failure, and
one patient died due to cancer of unknown primary ori-
gin. The Kaplan-Meier PAH-survival rate was 100%
after 1 and 2 years, and 80% after 3 years (Figure 4).
The overall survival rate was 100% after 1 and 2 years,
and 73% after 3 years. The transplantation-free survival
rate was 95% after 1 and 2 years (Figure 4).
ET was continued over 3 years by 11 patients (61%).
They reported a mean ET-duration of 29 ± 18 minutes
at 4 ± 2 days/week. Among the 11 patients, 44% contin-
ued bicycle ergometer training, 17% dumbbell-training,
33% walking and 22% alternative training, such as gym-
nastics. Four patients (22%) combined two training
items and three patients (17%) combined three items.
Six patients (33%) stopped exercise training for the fol-
lowing reasons: pain, presyncopes, no permanent
instruction and confidence with general state of health.
Discussion
This is the first prospective clinical trial investigating
short- and long-term effects of ET as an add-on to
PAH-targeted medication in patients with severe CTD-
APAH. The results of the study suggest that ET can sig-
nificantly improve prognostic relevant parameters such
as exercise capacity and QoL in this condition, and has
an excellent long-term survival of 100% after 2 years
and 80% after 3 years.
Figure 2 Mean short-form Health Survey Questionnaire (SF-36) scores for quality of life subscales before and after exercise training. At
baseline (straight line), mean SF-36 scores were significantly reduced in comparison to respective values from a normal population (dotted line).
After 15 weeks (dashed line), 5 scales of the SF-36 questionnaire improved significantly: physical functioning, general health perception, social
functioning, mental health and vitality. P-values are indicated vs. baseline. No significant improvement was found for role emotional (ROLEM),
role physical (ROLPH) and bodily pain (PAIN) after training. With Bonferroni adjustment, values of P < 0.005 were considered statistically
significant. Data were available and were included in the analyses for 21 patients studied at baseline and for 18 patients studied at 15 weeks.
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Table 2 Efficacy parameters
Characteristic Baseline (n = 21) 3 weeks (n = 21) P-value 15 weeks (n = 14) P-value
6-minute walking distance, m
Mean change 386 ± 121 425 ± 118 447 ± 139
64 ± 17 < 0.001a 71 ± 35 0.003
95% CI for the difference to baseline 42 - 85 48 - 95
Quality of life questionnaire SF36, score
Physical functioning 33.5 ± 20 0.025b 45.2 ± 20 0.025b
Role-physical 60.4 ± 36 0.317 65.6 ± 23 0.317
Bodily pain 58.1 ± 33 0.260 62.2 ± 31 0.260
General health perception 31.6 ± 15 0.049b 35.9 ± 14 0.049b
Vitality 38.1 ± 14 0.021b 48.1 ± 18 0.021b
Social functioning 61.8 ± 30 0.008a 71.4 ± 23 0.008a
Role-emotional 77.6 ± 22 0.115 91.6 ± 14 0.115
Mental Health 56.8 ± 21 0.033b 66.2 ± 16 0.033b
Cardiopulmonary exercise testing
Peak VO2/kg, mL/min/kg 11.8 ± 3.4 13.6 ± 3.4 0.010
b 14.1 ± 3.5 0.008a
Peak VO2, ml/min 822 ± 252 882 ± 218 0.011
b 887 ± 139 0.007a
EqCO2 at AT, ml/min 41.3 ± 8.9 41.3 ± 9.5 0.529 42.8 ± 7.1 0.138
VO2 at AT; ml/min 619 ± 172 689 ± 207 0.013
b 681 ± 207 0.012b
Oxygen pulse, (mL/min)/min-1 6.7 ± 1.6 6.8 ± 1.8 0.127 6.3 ± 0.4 0.260
HR rest, min-1 85 ± 14 77 ± 12 0.0001a 78 ± 16 0.045b
HR max, min-1 122 ± 21 127 ± 18 0.076 140 ± 20 0.005a
RRsys rest, mmHg 117 ± 17 114 ± 15 0.092 111 ± 15 0.653
RRdiast rest, mmHg 75 ± 8 71 ± 9 0.038b 72 ± 8 0.464
RRsys max, mmHg 149 ± 28 154 ± 18 0.743 153 ± 18 0.002a
RRdias max, mmHg 85 ± 13 88 ± 14 0.292 88 ± 12 0.083
Oxygen saturation rest, % 94.7 ± 3.0 96.7 ± 3.2 0.266 96.4 ± 2.8 0.421
Oxygen saturation max, % 89.8 ± 5.6 90.8 ± 5.8 0.052 91.7 ± 6.3 0.018b
sPAP rest, mmHg 52 ± 14 47 ± 9 0.005a 50 ± 10 0.210
sPAP max, mmHg 85 ± 26 87 ± 20 0.959 89 ± 14 0.320
Workload max, W 55 ± 19 67 ± 23 0.007a 65 ± 20 0.008a
Borg Scale, score 16 ± 2 15 ± 2 0.171 15 ± 1 0.105
Laboratory parameters
C-reactive protein, mg/l 15.2 ± 22.5 8.3 ± 9.7 0.069 6.6 ± 5.3 0.071
Leucocytes, 109/l 9.2 ± 7.5 10.0 ± 12.9 0.071 8.6 ± 7.6 0.177
NT-proBNP, pg/ml 1928 ± 4623 1101 ± 1380 0.164 2321 ± 2671 0.646
Values are mean ± standard deviation. aP < 0.01, bP < 0.05 in comparison to baseline; P-values are the same for absolute values and differences. 6-minute walking distance data were analyzed by the two-sided
Student t-test; cardiopulmonary exercise testing data were analyzed by the Wilcoxon test. CI: confidence interval; SF-36: short-form Health Survey Questionnaire; VO2/kg: maximum oxygen consumption/kg; EqCO2:

















The results represent an important source of data on
survival, exercise capacity and QoL in patients with
CTD-APAH treated with ET. The 6MWD, QoL
questionnaire (SF-36), peak oxygen consumption, oxy-
gen consumption at the AT, maximal oxygen saturation
and maximal workload increased significantly with ET
Figure 3 Workload compared to the Borg scale. The figure shows a significant increase in workload after 3 and 15 weeks (P = 0.007 and P =
0.008). The Borg scale remained unchanged (P = 0.171 and P = 0.105, respectively) although significantly higher workloads and higher heart
rates during exercise were attained. Values are indicated as the mean, and the bars represent standard deviation. The columns represent
workload (measured in Watt) and the dotted line the Borg Scale.
Figure 4 Survival by Kaplan-Meier analysis. Within a follow-up period of 2.9 ± 1.9 years (25 ± 13 months), two patients died due to
pulmonary hypertension (PH), one died due to carcinoma, and one patient underwent lung transplantation. The dashed line indicates mortality
due to connective tissue disease-associated pulmonary arterial hypertension (CTD-APAH), the straight line indicates overall survival, and the
dotted line indicates transplantation-free survival. The Kaplan-Meier PAH-survival rate was 100% after 1, and 2 years, and 80% after 3 years. The
overall survival rate was 100% after 1, and 2 years, and 73% after 3 years. The transplantation-free survival rate was 95% after 1 and 2 years.
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after 3 and 15 weeks. RRdiast and sPAP significantly
decreased after 3 weeks. This may be due to an
improvement in endothelial dysfunction. Nevertheless,
due to the limited number of patients we cannot
exclude that these improvements occurred coinciden-
tally. The Borg scale remained unchanged although sig-
nificantly higher workloads and higher heart rates
during exercise were attained. These results are in line
with previous studies of ET in patients with other forms
of PH/PAH [13-15]. There are few data on exercise
training in CTD. In patients with SSc but not PAH, ET
has improved QoL parameters (SF-36) and heart rate at
rest [19], 6 MWD [18] and muscle strength [17]. Quality
of life and peak VO2 have also been significantly amelio-
rated by training in patients with SLE without PAH [16].
Survival of patients with CTD-APAH after training
The Kaplan-Meier overall survival rate of 100% after 1
and 2 years and 73% (80% PH-related survival) after 3
years, using ET as add-on to optimized PAH-targeted
medical treatment, can be considered a positive out-
come in CTD-APAH. Despite optimized PAH-targeted
therapy, the Reveal registry showed a 1-year survival in
patients with SSC-APAH of only 82% vs. 84% in SLE-
APAH, 88% in MCTD-APAH and 93% in IPAH [7]. In
two trials of bosentan in CTD-APAH-patients, the
Kaplan-Meier estimates of survival were 85.9% and
73.4% after 1 and 2 years, respectively [23]. The 3-year
survival rate in SSc-APAH was 60% vs. 78% in IPAH
[8]. Similar patterns have been seen in the UK registry
[9] and the French registry [24,25] and in several further
studies [26]. These data indicate that patients with
CTD-APAH represent a high-risk subgroup of patients
with PAH. The CTD-APAH-cohort assessed in this
study had been severely affected with a mean 6MWD of
386 ± 121 meters at baseline despite double or even tri-
ple PAH-targeted therapy in 62% of patients, and is
therefore comparable to the cohorts described pre-
viously. We cannot exclude that we selected highly
motivated and compliant patients with fewer outcome
limitations. In addition, the number of patients in our
study was quite small. Nevertheless, ET may have
improved survival by ameliorating prognostic relevant
factors such as QoL, exercise capacity and oxygen con-
sumption. Since heart rate at rest, RRdiast and peak
oxygen consumption significantly improved, ET possibly
improved right ventricular reserve [14]. Similar effects
of ET have been seen in patients with IPAH and
CTEPH and right heart failure [14,15].
Improvement in 6-minute-walking distance
The 6MWD has been used as primary endpoint in
many randomized controlled clinical trials in PAH [1],
and correlates with prognostic relevant clinical
parameters such as WHO-FC in patients with SSc-PAH
[6]. However, the test is not sufficiently validated in
CTD-APAH and in patients with rheumatic diseases in
particular, it is influenced by comorbidity and muscu-
loskeletal limitations [6,27]. This has been taken as
explanation for the fact that 6MWD in patients with
CTD-APAH is at best only minimally improved by
PAH-targeted medication. In randomized controlled
trials, sildenafil is the only drug to have been associated
with a significant increase in 6MWD in patients with
CTD-APAH (in many other trials no subgroup analysis
for this disease has been performed). Therefore, a mean
increase of almost 70 meters after 3 and 15 weeks ET is
unexpectedly high. The absence of a non-trained pla-
cebo group may be considered a limitation of the study,
with concern that some of the improvements were due
to the so-called placebo effect, rather than efficacy of
ET. However, previously reported placebo-controlled
PAH studies of bosentan or other PAH-specific treat-
ments have not shown any clinically relevant improve-
ments in the placebo groups. In fact, they have
consistently shown a continuous decline in 6MWD.
Therefore, the results of this study suggest that, espe-
cially in CTD-APAH-patients with known high coinci-
dence of musculoskeletal limitations, ET as an add-on
to PAH-targeted medication may be useful, and possibly
even more effective in improving exercise capacity than
medical treatment. Further randomized trials are needed
to clarify this question.
Limitations
The results of this prospective study are promising and
our data provide a good rationale for future studies of
exercise training in patients with CTD-APAH. However,
the positive results may also be influenced by the small
sample size. Larger, randomized controlled and multi-
centric studies are needed to determine the effectiveness
of exercise training in CTD-APAH. The effects of ET
after 15 weeks may be biased due to the missing values
of about 43% of patients who did not perform the last
follow-up visit. A comparison between patients who
completed the 15 week assessment and those who did
not revealed that patients who dropped out had even
better improvement in efficacy parameters after 3 weeks
in-hospital rehabilitation. This suggests that they possi-
bly did not attend because they felt better. Feedback
from patients during follow-up visits supports this
assumption.
It is a general issue of rehabilitation programs that the
therapy cannot be performed in a blinded fashion and
that a referral bias towards highly motivated patients
with a better outcome may occur. Further studies are
necessary to determine the effects of training programs
on outcome in patients with PH.
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Conclusion
This is the first trial investigating exercise training in
CTD-APAH as an add-on to optimized medical therapy.
The results indicate that ET is effective in CTD-APAH
and may improve work capacity, QoL and further prog-
nostic relevant parameters, and possibly improves the 1-
, 2- and 3-year survival rate. Further randomized con-
trolled studies are needed to confirm these results.
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long Term PAH Disease Management; RRdiast: diastolic systemic blood
pressure; RRsys: systolic systemic blood pressure; SD: standard deviation; SF-
36: short form Health Survey Questionnaire; SLE: systemic lupus
erythematosus; sPAP: systolic pulmonary arterial pressure; SSc: systemic
sclerosis; TLCO: carbon monoxide transfer factor; VCO2: carbon dioxide
output; VE: ventilation; VO2/heart rate: oxygen pulse; VO2: oxygen uptake;
WHO-FC: World Health Organization functional class.
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